Eli Lilly and Company (LLY)
| Market Cap | 739.20B |
| Revenue (ttm) | 35.93B |
| Net Income (ttm) | 6.14B |
| Shares Out | 950.41M |
| EPS (ttm) | 6.79 |
| PE Ratio | 114.55 |
| Forward PE | 57.80 |
| Dividend | $5.20 (0.67%) |
| Ex-Dividend Date | May 15, 2024 |
| Volume | 2,842,406 |
| Open | 768.90 |
| Previous Close | 766.68 |
| Day's Range | 762.11 - 779.09 |
| 52-Week Range | 419.80 - 800.78 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 737.05 (-5.24%) |
| Earnings Date | Apr 30, 2024 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the... [Read more]
Financial Performance
In 2023, LLY's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $737.05, which is a decrease of -5.24% from the latest price.
News
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
Eli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch's heart monitoring tech was approved for use in clinical studies.
US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10
Eli Lilly said on Tuesday a panel of independent U.S. FDA advisers will discuss whether the agency should approve its Alzheimer's disease drug, donanemab, on June 10.
Lilly Declares Second-Quarter 2024 Dividend
INDIANAPOLIS , May 6, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common s...
Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
Amgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.
Wegovy, Mounjaro prices cut as British pharmacies compete for weight-loss patients
Online pharmacies and slimming clinics are cutting prices for Wegovy and Mounjaro in Britain just months after the weight-loss drugs were launched there, as initial supply shortages ease.
Trade Tracker: Joe Terranova sells Eli Lilly
The Investment Committee discusses the healthcare sector as Joe Terranova sells Eli Lilly in his JOET rebalance.
Potential for Weight-Loss Drugs Boosts Eli Lilly
Eli Lilly & Co.'s shares soared as its brighter outlook for 2024 raised the potential ceiling for new weight-loss drugs even further in the eyes of analysts and investors. Lilly says supply and pricin...
Eli Lilly stock soars on earnings, 'off-the-charts' demand for weight-loss drugs
Shares of Eli Lilly (LLY) are soaring in Tuesday's trading session after the company raised its full-year guidance, driven by the surging demand for its offerings. BMO Capital Markets BioPharma Equity...
Eli Lilly Leaps After Earnings
Biopharmaceutical giant Eli Lilly raised full-year guidance after reporting a 26% year-over-year revenue rise in its 1st quarter. Led by sales of obesity & diabetes drugs, Eli Lilly's chart has flirte...
Eli Lilly Stock Surges on Demand for Weight-Loss Drugs
Eli Lilly beat earnings expectations for the first quarter and raised its outlook for the year.
Eli Lilly (LLY) stock soars, Q1 earnings results show 26% revenue growth
The Eli Lilly And Company (NYSE: LLY) stock has jumped +53.33 (7.23%) after the company reported strong financial performance in its Q1 earnings report. At press time, the Eli Lilly stock was trading ...
Eli Lilly Stock Surges as Weight Loss Drugs Continue to Fuel Growth
Eli Lilly (LLY) stock jumped in early trading Tuesday after the drugmaker reported first-quarter earnings that beat analysts' expectations and raised its guidance thanks to continued high demand for t...
Eli Lilly is a 'multi-diversified drugmaker', says Cantor Fitzgerald's Louise Chen
Louise Chen, Cantor Fitzgerald managing director, joins 'Squawk Box' to discuss Eli Lilly's quarterly earnings results, weight loss drug demand, growth outlook, and more.
Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more product
Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's weight loss drugs, growth outlook, and more.
Morning Minute: Tuesday, April 30
Nvidia catches a price target hike, while Tesla's workforce sees more layoffs. Plus, Eli Lilly flirts with all-time highs after hiking full-year guidance in its latest earnings report.
Eli Lilly Stock Jumps After Earnings Beat. Weight-Loss Drugs Are Driving Gains.
The pharmaceutical company reported adjusted earnings of $2.58 a share for the first quarter of 2024, up 59% from the same period a year earlier. Revenue rose 26% to $8.77 billion.
Eli Lilly's stock jumps as first-quarter profit tops estimates amid strong sales of Mounjaro, Zepbound
Eli Lilly & Co. shares gained more than 5% premarket on Tuesday after the company reported first-quarter profit that topped analyst expectations amid strong sales of diabetes drug Mounjaro and weight-...
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro
Zepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.
Eli Lilly lifts profit view on diabetes and weight-loss drug strength
Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro.
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; ...
Earnings Exchange: McDonald's, Brinker International, Eli Lilly
Ari Wald, Oppenheimer head of technical analysis, joins CNBC's 'The Exchange' to discuss earnings from McDonald's, Brinker International, and Eli Lilly.
Cramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly
CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.
What You Need To Know Ahead of Eli Lilly's Earnings Report Tuesday
Eli Lilly (LLY) reports earnings before the bell Tuesday, with investors and analysts watching to see how much weight-loss drugs are continuing to drive the company's growth.
A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly's Q1
Eli Lilly stock (NYSE: LLY) will report its Q1 results on Tuesday, April 30. The pharmaceutical giant is expected to garner $8.9 billion in sales and $2.46 in adjusted earnings per share, per the cons...